BOCOM INTL: Raised target price of SINO BIOPHARM (01177) to HK$8, maintain "buy" rating.
ReXin Pharmaceutical will become a wholly-owned subsidiary of Chinese biopharmaceuticals, and its main research and management team, along with its dual antibody, ADC, and other technology platforms, will join Chinese biopharmaceuticals.
BOCOM INTL released a research report stating that the efforts of SINO BIOPHARM (01177) in acquisition and cost reduction have shown significant results. The adjusted net profit forecast for 2025-27 has been raised by 10-11%, and the target price has been raised to HK$8. The "Buy" rating is maintained, with short-term catalysts including potential BD authorization opportunities for the company's self-developed pipeline.
The report states that the group announced its intention to acquire 95.09% equity of Li Xin Pharmaceutical for a transaction value not exceeding US$951 million. Excluding Li Xin Pharmaceutical's estimated cash and bank deposits of approximately US$450 million on the delivery date, the net payment amount to be made for the acquisition is approximately US$501 million. After the completion of this transaction, Li Xin Pharmaceutical will become a wholly-owned subsidiary of SINO BIOPHARM, and its main research and management team, along with its dual antibody, ADC, and other technology platforms, will join SINO BIOPHARM.
Related Articles

US Stock Market Move | The latest "meme stock" is out! Kohl's (KSS.US) surged nearly 90% at one point.

US Stock Market Move | Daqo New Energy Corp Sponsored ADR (DQ.US) surged by nearly 17%, Citigroup initiates coverage with a "buy" rating and a target price of $27.

US Stock Market Move | General Motors Company (GM.US) fell 7.7% at one point, with the Chief Financial Officer predicting that the impact of tariffs could reach up to $5 billion this year.
US Stock Market Move | The latest "meme stock" is out! Kohl's (KSS.US) surged nearly 90% at one point.

US Stock Market Move | Daqo New Energy Corp Sponsored ADR (DQ.US) surged by nearly 17%, Citigroup initiates coverage with a "buy" rating and a target price of $27.

US Stock Market Move | General Motors Company (GM.US) fell 7.7% at one point, with the Chief Financial Officer predicting that the impact of tariffs could reach up to $5 billion this year.

RECOMMEND

U.S. Congressional Budget Office: “Big and Beautiful” Act to Increase Deficit by $3.4 Trillion
22/07/2025

Fierce Midfield Battle for AI Talent: Domestic Shortage Reaches 5 Million While Overseas Giants Offer Multimillion-Dollar Salaries
22/07/2025

National-Level Housing Rental Regulations Issued to Strictly Regulate Fake Listings, Group Rentals, and Irregular Rent-to-Loan Practices
22/07/2025